Regorafenib for metastatic or unresectable GIST (after failure of at least previous imatinib and sunitinib) is listed on the current National Cancer Drugs Fund List (last updated March 2015; version 4.0). It has been subject to a formal appeal, which has been upheld in part, and it will be reconsidered by the CDF Panel in due course. It will remain available through the CDF until this process is completed and subject to the final outcome.